Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15684270 | 0.82 | BRD4 (0.63) | BRD4MAPTPOLBSMN1; SMN2CASP1 | |
| SCHEMBL119901 | 0.82 | BRD4 (0.63) | BRD4MAPTPOLBSMN1; SMN2CASP1 | |
| SCHEMBL2811918 | 0.82 | BRD4 (0.63) | BRD4MAPTPOLBSMN1; SMN2CASP1 | |
| SCHEMBL30307671 | 0.82 | BRD4 (0.63) | BRD4MAPTPOLBSMN1; SMN2CASP1 | |
| SCHEMBL3826960 | 0.76 | BRD4 (0.53) | BRD4MAPTPOLBSMN1; SMN2CASP1 | |
| Glycerin SCHEMBL3843494 | 0.74 | MAPT (0.51) | BRD4MAPTPOLBALOX15SMN1; SMN2 | |
| SCHEMBL23795093 | 0.72 | POLB (0.46) | MAPTPOLBALOX15SMN1; SMN2KMT2A | |
| SCHEMBL9789649 | 0.72 | BRD4 (0.59) | BRD4MAPTPOLBCASP1CASP7 | |
| Triethylene Glycol SCHEMBL1362131 | 0.72 | BRD4 (0.51) | BRD4MAPTPOLBSMN1; SMN2CASP1 | |
| SCHEMBL21948726 | 0.70 | BRD4 (0.56) | BRD4MAPTPOLBSMN1; SMN2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796472-B2 | Mixtures of itaconic acid or itaconic acid derivatives and primary amines for producing 1,3- and 1,4-alkyl methyl pyrrolidones | BASF SE (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20110251119-A1 | MIXTURES OF ITACONIC ACID OR ITACONIC ACID DERIVATIVES AND PRIMARY AMINES FOR PRODUCING 1,3- AND 1,4-ALKYL METHYL PYRROLIDONES | BASF SE (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251119-A1 | MIXTURES OF ITACONIC ACID OR ITACONIC ACID DERIVATIVES AND PRIMARY AMINES FOR PRODUCING 1,3- AND 1,4-ALKYL METHYL PYRROLIDONES | HADHA, HADH, ASS1 | BRD4 651/4885MAPT 1703/4885POLB 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.